| 3 | One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches显示文摘Exocrine pancreatic neoplasms represent up to 95%of pancreatic cancers(PCs)and are widely recognized among the most lethal solid cancers,with a very poor 5-year survival rate of 5%-10%.The remaining<5%of PCs are neuroendocrine tumors that are usually characterized by a better prognosis,with a median overall survival of 3.6 years.The most common type of PC is pancreatic ductal adenocarcinoma(PDAC),which accounts for roughly 85%of all exocrine PCs.However up to 10%of exocrine PCs have rare histotypes,which are still poorly understood.These subtypes can be distinguished from PDAC in terms of pathology,imaging,clinical presentation and prognosis.Additionally,due to their rarity,any knowledge regarding these specific histotypes is mostly based on case reports and a small series of retrospective analyses.Therefore,treatment strategies are generally deduced from those used for PDAC,even if these patients are often excluded or not clearly represented in clinical trials for PDAC.For these reasons,it is essential to collect as much information as possible on the management of PC,as assimilating it with PDAC may lead to the potential mistreatment of these patients.Here,we report the most significant literature regarding the epidemiology,typical presentation,possible treatment strategies,and prognosis of the most relevant histotypes among rare PCs. | Monica Niger Michele Prisciandaro Maria Antista Melissa Anna Teresa Monica Laura Cattaneo Natalie Prinzi Sara Manglaviti Federico Nichetti Marta Brambilla Martina Torchio Francesca Corti Sara Pusceddu Jorgelina Coppa Vincenzo Mazzaferro Filippo de Braud Maria Di Bartolomeo | 2020 | World Journal of Gastrointestinal Oncology2020，12，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员